The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
3 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $2,782,638 in first-year total cost, median $830,691.
Most frequent study sections
- Special Emphasis Panel[ZDA1 HXO-H (15)]3
Most frequent institutions
- JOHNS HOPKINS UNIVERSITY1
- UNIVERSITY OF WASHINGTON1
- YALE UNIVERSITY1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2018 | Pharmacogenomics of ART adherence and effectiveness in the ALIVE Cohort1R01DA047064-01 | KIRK, GREGORY DMAHER, BRION S | JOHNS HOPKINS UNIVERSITY, MD | $1,389,208 | ZDA1 |
| 2018 | Genes, substance use, and HIV outcomes in people living with HIV across the US1R01DA047045-01 | CRANE, HEIDI M.PETER, INGA | UNIVERSITY OF WASHINGTON, WA | $830,691 | ZDA1 |
| 2018 | Defining the impact of injection drug use on antiretroviral therapy and HIV treatment outcomes: an (epi)genomic approach1R01DA047063-01 | AOUIZERAT, BRADLEY EXU, KE | YALE UNIVERSITY, CT | $562,739 | ZDA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.